JP2020513759A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513759A5
JP2020513759A5 JP2019534413A JP2019534413A JP2020513759A5 JP 2020513759 A5 JP2020513759 A5 JP 2020513759A5 JP 2019534413 A JP2019534413 A JP 2019534413A JP 2019534413 A JP2019534413 A JP 2019534413A JP 2020513759 A5 JP2020513759 A5 JP 2020513759A5
Authority
JP
Japan
Prior art keywords
seq
antibody
substantially similar
sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019534413A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020513759A (ja
JP7122758B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/068368 external-priority patent/WO2018119474A2/en
Publication of JP2020513759A publication Critical patent/JP2020513759A/ja
Publication of JP2020513759A5 publication Critical patent/JP2020513759A5/ja
Application granted granted Critical
Publication of JP7122758B2 publication Critical patent/JP7122758B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019534413A 2016-12-23 2017-12-23 プログラム死-1(pd-1)に結合する抗体を使用する免疫療法 Active JP7122758B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662438949P 2016-12-23 2016-12-23
US62/438,949 2016-12-23
PCT/US2017/068368 WO2018119474A2 (en) 2016-12-23 2017-12-23 Immunotherapy using antibodies that bind programmed death 1 (pd-1)

Publications (3)

Publication Number Publication Date
JP2020513759A JP2020513759A (ja) 2020-05-21
JP2020513759A5 true JP2020513759A5 (enExample) 2021-02-04
JP7122758B2 JP7122758B2 (ja) 2022-08-22

Family

ID=62627200

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019534413A Active JP7122758B2 (ja) 2016-12-23 2017-12-23 プログラム死-1(pd-1)に結合する抗体を使用する免疫療法

Country Status (6)

Country Link
US (1) US11248049B2 (enExample)
EP (1) EP3559044A4 (enExample)
JP (1) JP7122758B2 (enExample)
CN (1) CN110366564B (enExample)
RU (1) RU2768404C2 (enExample)
WO (1) WO2018119474A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
WO2020259536A1 (zh) 2019-06-24 2020-12-30 南京金斯瑞生物科技有限公司 单克隆抗体-细胞因子融合蛋白二聚体及其应用
EP3998081A4 (en) 2019-07-05 2023-07-12 Ono Pharmaceutical Co., Ltd. TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN
JP7771749B2 (ja) 2019-08-08 2025-11-18 小野薬品工業株式会社 二重特異性タンパク質
EP4039704A4 (en) * 2019-09-30 2023-09-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ANTI-PD-1 ANTIBODIES AND USE THEREOF
MX2023005386A (es) * 2020-11-11 2023-05-23 BioNTech SE Anticuerpos monoclonales dirigidos contra la proteina de muerte programada-1 y su uso en medicina.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753912B (zh) * 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
ES2720160T3 (es) * 2005-05-09 2019-07-18 Ono Pharmaceutical Co Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
ES2460517T3 (es) * 2005-07-25 2014-05-13 Emergent Product Development Seattle, Llc Reducción de células b mediante el uso de moléculas de unión específica a cd37 y de unión específica a cd20
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CA2673870A1 (en) * 2006-12-27 2008-07-10 Emory University Compositions and methods for the treatment of infections and tumors
JP5191537B2 (ja) * 2007-06-18 2013-05-08 エム・エス・ディー・オス・ベー・フェー ヒトのプログラムされたデスレセプターpd−1に対する抗体
EP2262837A4 (en) * 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
BR112014024023A2 (pt) * 2012-03-28 2017-07-18 Genentech Inc anticorpos idiotípicos anti-hcmv e usos dos mesmos
JP6324974B2 (ja) * 2012-10-12 2018-05-23 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ タウの毒性オリゴマー形態を特異的に認識する抗体ベースの試薬
KR102243062B1 (ko) 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
CN104250302B (zh) * 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
US9629801B2 (en) * 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
FI128317B (fi) 2014-07-03 2020-03-13 Serres Oy Tyhjennyslaite, kokoonpano ja menetelmä imupussin tyhjentämiseksi
JP6986965B2 (ja) * 2014-07-22 2021-12-22 アポロミクス インコーポレイテッド 抗pd−1抗体
US10822414B2 (en) 2014-11-11 2020-11-03 Sutro Biopharma, Inc. Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
CA3175979A1 (en) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
TW201710286A (zh) * 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
CN106008714B (zh) * 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用

Similar Documents

Publication Publication Date Title
JP2020514277A5 (enExample)
JP2020513759A5 (enExample)
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
JP2020508655A5 (enExample)
JP2022031635A5 (enExample)
JP2017535257A5 (enExample)
JP7257971B6 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2017149720A5 (enExample)
RU2019121106A (ru) Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1)
JP2015163068A5 (enExample)
JP2015503909A5 (enExample)
JP2018510636A5 (enExample)
RU2017102514A (ru) Гуманизированные анти-тау-антитела
JP2018510617A5 (enExample)
JP2018522888A5 (enExample)
JP7679399B2 (ja) 抗flt3抗体及び組成物
JP2020502233A5 (enExample)
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP2019505477A5 (enExample)
JP2016518333A5 (enExample)
JP2020531003A5 (enExample)
JP2016529213A5 (enExample)
JP2018529672A5 (enExample)
JPWO2020227457A5 (enExample)